- Vyas Group: Normal and Malignant Haematopoiesis Lab Research Group
I am a Research Fellow and Clinical Haematologist with a specialist interest in Myelodysplastic syndromes and Acute Myeloid Leukaemia (AML). These are oligoclonal myeloid malignancies where genetically distinct clones can result in differences in leukaemia cell function within individual patients. I am investigating how clonal heterogeneity affects the biology of leukaemia stem cells in MDS and AML, in particular response to novel anti-leukaemic therapies. I am integrating genomic and functional approaches, including single cell techniques to elucidate clonal structures, epigenetic and transcriptional heterogeneity. My research and clinical interest converge on the common goal to develop better therapies to MDS and AML patients.
Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia.
Mettananda S. et al, (2017), Nat Commun, 8
Identifying the optimum source of mesenchymal stem cells for use in knee surgery.
Davies BM. et al, (2017), J Orthop Res, 35, 1868 - 1875
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.
Amatangelo MD. et al, (2017), Blood, 130, 732 - 741
A NOVEL MODEL OF HUMAN LYMPHO-MYELOID PROGENITOR HIERARCHY BASED ON SINGLE CELL FUNCTIONAL AND TRANSCRIPTIONAL ANALYSIS
Karamitros D. et al, (2017), HAEMATOLOGICA, 102, 20 - 20
MOLECULAR PREDICTORS OF RESPONSE TO AZACITIDINE THERAPY: THE RESULTS OF THE UK TRIALS ACCELERATION PROGRAMME RAVVA STUDY
Craddock C. et al, (2017), HAEMATOLOGICA, 102, 323 - 323